Literature DB >> 21526101

Trend of prostate cancer in Fars Province, Southern Iran, 2001-2007.

Mahin Farahmand1, Farnaz Khademolhosseini, Davood Mehrabani.   

Abstract

Entities:  

Year:  2010        PMID: 21526101      PMCID: PMC3082826     

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


× No keyword cloud information.
In the United States, the estimates for prostate cancer in 2008 included over 186000 new cases and about 28700 deaths.1 It is one of the two most common malignancies among men in Gulf Cooperation Council countries.2 In Iran, prostate cancer has an incidence of 9.6 per 100,000, ranging from 3.2 to 16.0 per 100,000 in different geographical settings.3 This study aims to determine the trend of prostate cancer in Fars Province, Southern Iran. On a population based cancer registry, all cases of prostate cancer diagnosed in Fars Province, southern Iran from April 2001 to April 2007 were enrolled. Data were collected from all private and public pathology centers as well as forensic medicine laboratories and death/birth registries in the province. After coding the data according to ICD-O, they were classified and recorded in a computer database. Demographic data including age, residential area and morphology of the tumor were recorded. A total of 1102 cancer patients were registered. Out of these patients, 134 cases (12.5%) were resided outside Fars Province and the residential address of 110 cases (9.98%) was not found in the patient’s records. The incidence of prostate cancer had an increasing trend from 3.24 cases per 100,000 in 2001 to 14.21 cases per 100,000 in 2007 (Figure 1). The actual number of diagnosed prostate cancer cases increased from 64 in 2001 to 285 in 2007. The incidence rate was constant through 2001 to 2004 with a dramatic increase from 2004 to 2007. Improvement in surveillance systems and cancer registration may partly explain the increase in incidence.
Figure 1

Incidence of prostate cancer in Fars Province, Southern Iran during 2001-2007

Incidence of prostate cancer in Fars Province, Southern Iran during 2001-2007 This result on incidence is similar to that of Mousavi, who reported the incidence rate from 3.2 to 16.0 per 100,000 in different regions.3 The increasing trend in Fars Province is identical to Matsuda et al report in Asia showing an increasing trend except in India, where there was no obvious increase and decrease.4 Figure 2 shows that there is no diagnosed case of prostate cancer under the age of 30, and the rate increases with age. These results are similar to those of Mehrabani et al study in Fars with no cases of prostate cancer under the age of 25, and with an age increasing trend,5 and to that of Parkin et al who reported that 75% of prostate cancers were in age group of ≥ 65 years.6
Figure 2

Frequency distribution of prostate cancer according to age in Fars Province, Southern Iran in 2007

Frequency distribution of prostate cancer according to age in Fars Province, Southern Iran in 2007 The cumulative frequency of diagnosed prostate cancer in different cities of Fars Province is depicted in figure 3. A total of 529 patients were from Shiraz and then Kazeroun, Lar, and Mamasani had the highest frequencies. The relative frequency was lowest in 2001 (5.4%) and increased to its highest value (10.04%) in 2005, but since then it declined and reached 8.9% in 2007. Morphology of tumor for all prostate cancer was consistently found to be adenocarcinoma.
Figure 3

Cumulative frequency of prostate cancer in different cities of Fars Province, Southern Iran during 2001-2007

Cumulative frequency of prostate cancer in different cities of Fars Province, Southern Iran during 2001-2007 These findings should be taken into account in future health and medical planning.
  5 in total

1.  Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX.

Authors:  Tomohiro Matsuda; Kumiko Saika
Journal:  Jpn J Clin Oncol       Date:  2009-07       Impact factor: 3.019

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  Incidence of cancer in Gulf Cooperation Council countries, 1998-2001.

Authors:  N Al-Hamdan; K Ravichandran; J Al-Sayyad; J Al-Lawati; Z Khazal; F Al-Khateeb; A Abdulwahab; A Al-Asfour
Journal:  East Mediterr Health J       Date:  2009 May-Jun       Impact factor: 1.628

4.  Toward prostate cancer early detection in Iran.

Authors:  Seyed Mohsen Mousavi
Journal:  Asian Pac J Cancer Prev       Date:  2009 Jul-Sep

5.  Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California.

Authors:  Iona Cheng; John S Witte; Laura A McClure; Sarah J Shema; Myles G Cockburn; Esther M John; Christina A Clarke
Journal:  Cancer Causes Control       Date:  2009-06-13       Impact factor: 2.506

  5 in total
  6 in total

1.  Association between LAPTM4B gene polymorphism and prostate cancer susceptibility in an Iranian population.

Authors:  Mohammad Hashemi; Maryam Rezaei; Behzad Narouie; Nasser Simforoosh; Abbas Basiri; Sayed Amir Mohsen Ziaee; Gholamreza Bahari; Mohsen Taheri
Journal:  Mol Cell Oncol       Date:  2016-04-15

2.  Evaluation of a 3-base pair indel polymorphism within pre-microRNA-3131 in patients with prostate cancer using mismatch polymerase chain reaction-restriction fragment length polymorphism.

Authors:  Mohammad Hashemi; Gholamreza Bahari; Hedieh Sattarifard; Behzad Narouie
Journal:  Mol Clin Oncol       Date:  2017-08-08

3.  Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer.

Authors:  Mohammad Hashemi; Shadi Amininia; Mahboubeh Ebrahimi; Nasser Simforoosh; Abbas Basiri; Seyed Amir Mohsen Ziaee; Behzad Narouie; Mehdi Sotoudeh; Mohammad Javad Mollakouchekian; Esmaeil Rezghi Maleki; Hamideh Hanafi-Bojd; Maryam Rezaei; Gholamreza Bahari; Mohsen Taheri; Saeid Ghavami
Journal:  Oncol Lett       Date:  2017-02-14       Impact factor: 2.967

4.  Association between single nucleotide polymorphism in miR-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian population.

Authors:  Mohammad Hashemi; Nazanin Moradi; Seyed Amir Mohsen Ziaee; Behzad Narouie; Mohammad Hosein Soltani; Maryam Rezaei; Ghazaleh Shahkar; Mohsen Taheri
Journal:  J Adv Res       Date:  2016-03-29       Impact factor: 10.479

5.  Healthy Plant Foods Intake Could Protect Against Prostate Cancer Risk: A Case-Control Study

Authors:  Yahya Jalilpiran; Erfan Hezaveh; Salmeh Bahmanpour; Shiva Faghih
Journal:  Asian Pac J Cancer Prev       Date:  2017-07-27

Review 6.  The incidence of prostate cancer in Iran: a systematic review and meta-analysis.

Authors:  Soheil Hassanipour; Mohammad Fathalipour; Hamid Salehiniya
Journal:  Prostate Int       Date:  2017-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.